Lilly's tirzepatide was superior to placebo for MASH resolution

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine

Suven reports positive Phase 2b results for Ropanicant in major depressive disorder

Suven has already begun planning a global Phase 3 registrational program for MDD based on the results

UK approves Wegovy pill in major shift in obesity treatment options

Approval is based on results from the phase 3 OASIS 4 clinical trial

AstraZeneca reports major Phase III breakthrough in IgA kidney disease trial

At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide

The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format

Novo Nordisk's Zenagamtide shows strong HbA1c and weight loss benefits in phase II trial

Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions

Finerenone expands promise beyond diabetic kidney disease

The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized

Omnix Medical advances first-in-class antimicrobial OMN6 into Phase II trials

Targeting deadly drug-resistant acinetobacter infections

Omnix Medical doses first patients in phase II trial of antimicrobial lead compound OMN6

First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept